322 related articles for article (PubMed ID: 25541698)
21. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of semaphorin 3A in patients with urothelial cancer.
Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
[TBL] [Abstract][Full Text] [Related]
23. Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics.
Shao CH; Chen CL; Lin JY; Chen CJ; Fu SH; Chen YT; Chang YS; Yu JS; Tsui KH; Juo CG; Wu KP
Oncotarget; 2017 Jun; 8(24):38802-38810. PubMed ID: 28415579
[TBL] [Abstract][Full Text] [Related]
24. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of statistical techniques to normalize mass spectrometry-based urinary metabolomics data.
Cook T; Ma Y; Gamagedara S
J Pharm Biomed Anal; 2020 Jan; 177():112854. PubMed ID: 31518861
[TBL] [Abstract][Full Text] [Related]
26. NMR-based metabolomics study of canine bladder cancer.
Zhang J; Wei S; Liu L; Nagana Gowda GA; Bonney P; Stewart J; Knapp DW; Raftery D
Biochim Biophys Acta; 2012 Nov; 1822(11):1807-14. PubMed ID: 22967815
[TBL] [Abstract][Full Text] [Related]
27. Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
Yang C; Sun X; Wang H; Lu T; Wu K; Guan Y; Tang J; Liang J; Sun R; Guo Z; Zheng S; Wu X; Jiang H; Jiang X; Zhong B; Niu X; Sun S; Wang X; Chen M; Fu G
Int J Mol Med; 2019 Nov; 44(5):1952-1962. PubMed ID: 31545404
[TBL] [Abstract][Full Text] [Related]
28. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
30. Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.
Sin MLY; Mach KE; Sinha R; Wu F; Trivedi DR; Altobelli E; Jensen KC; Sahoo D; Lu Y; Liao JC
Clin Cancer Res; 2017 Jul; 23(14):3700-3710. PubMed ID: 28193625
[No Abstract] [Full Text] [Related]
31. Metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer.
Jobu K; Sun C; Yoshioka S; Yokota J; Onogawa M; Kawada C; Inoue K; Shuin T; Sendo T; Miyamura M
Biol Pharm Bull; 2012; 35(4):639-42. PubMed ID: 22466574
[TBL] [Abstract][Full Text] [Related]
32. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
33. CCL18 in a multiplex urine-based assay for the detection of bladder cancer.
Urquidi V; Kim J; Chang M; Dai Y; Rosser CJ; Goodison S
PLoS One; 2012; 7(5):e37797. PubMed ID: 22629457
[TBL] [Abstract][Full Text] [Related]
34. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
Alberice JV; Amaral AF; Armitage EG; Lorente JA; Algaba F; Carrilho E; Márquez M; García A; Malats N; Barbas C
J Chromatogr A; 2013 Nov; 1318():163-70. PubMed ID: 24139504
[TBL] [Abstract][Full Text] [Related]
35. A urinary microRNA (miR) signature for diagnosis of bladder cancer.
Hofbauer SL; de Martino M; Lucca I; Haitel A; Susani M; Shariat SF; Klatte T
Urol Oncol; 2018 Dec; 36(12):531.e1-531.e8. PubMed ID: 30322728
[TBL] [Abstract][Full Text] [Related]
36. Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer.
Nakashima M; Matsui Y; Kobayashi T; Saito R; Hatahira S; Kawakami K; Nakamura E; Nishiyama H; Ogawa O
Cancer Biomark; 2015; 15(4):357-64. PubMed ID: 26406865
[TBL] [Abstract][Full Text] [Related]
37. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer.
Mengual L; Lozano JJ; Ingelmo-Torres M; Gazquez C; Ribal MJ; Alcaraz A
Int J Cancer; 2013 Dec; 133(11):2631-41. PubMed ID: 23686449
[TBL] [Abstract][Full Text] [Related]
38. Targeted metabolomics in bladder cancer: From analytical methods development and validation towards application to clinical samples.
Yumba Mpanga A; Siluk D; Jacyna J; Szerkus O; Wawrzyniak R; Markuszewski M; Matuszewski M; Kaliszan R; Markuszewski MJ
Anal Chim Acta; 2018 Dec; 1037():188-199. PubMed ID: 30292293
[TBL] [Abstract][Full Text] [Related]
39. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
40. Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges.
Burton C; Ma Y
Curr Med Chem; 2019; 26(1):5-28. PubMed ID: 28914192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
